alexa Safety of Low Dose of Edoxaban to Treat Acute and Long Term Treatment of a VTE Occurred in a Very Young Adolescent | OMICS International| Abstract
ISSN: 2165-7831

Journal of Blood & Lymph
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Case Report   
  • J Blood Lymph 2017, Vol 7(4): 191
  • DOI: 10.4172/2165-7831.1000191

Safety of Low Dose of Edoxaban to Treat Acute and Long Term Treatment of a VTE Occurred in a Very Young Adolescent

Pierpaolo Di Micco1* and Gianluca Di Micco2
1Department of Medicine, UOC Internal Medicine, Ospedale Fatebenefratelli di Napoli, , Napoli, Italy
2Department of Medicine, UO Cardiology, Ospedale Fatebenefratelli di Napoli, , Napoli, Italy
*Corresponding Author : Pierpaolo Di Micco, Department of Medicine, UOC Internal Medicine, Ospedale Fatebenefratelli di Napoli, Napoli, Italy, Tel: 00393398078146, Email: [email protected]

Received Date: Nov 19, 2017 / Accepted Date: Nov 22, 2017 / Published Date: Nov 29, 2017

Abstract

The treatment of VTE with direct oral anticoagulant (DOACs) is a common treatment and therapeutic regimens and timing of treatment are well documented by international guidelines both for initial therapy and for extended therapy. Suggested doses of each drug are established after dose-findings studies and thereafter after phase III clinical trials. Suggested doses of edoxaban to treat VTE are based on 60 mg daily while other available dosages, in particular 30 mg daily are suggested if patients show impaired renal function with moderate kidney failure, low body weight or concomitant use of P-glycoprotein inhibitor drugs. However, there are not studies concerning the optimal treatment with any DOACs and in particular for edoxaban for patients aged less than 18 years, because in dose findings studies and in phase III trials alle selected subjects were major than 18 years old; these informations are also lacking in the Literature concerning real life studies too (e.g., case reports and so on). So 30 mg daily of edoxaban for patients younger than 18 years may be considered an off label target. Moreover the off label dosage of 30 mg daily of edoxaban to treat juvenile VTE is related not only to young age but also to other clinical characteristics as juvenile metabolism and body weight and BMI, gastrointestinal absorption and renal and liver metabolism. This report may so add useful information for a next future application of this kind of drugs also in young patients affected by VTE.

Citation: Micco PD, Micco GD (2017) Safety of Low Dose of Edoxaban to Treat Acute and Long Term Treatment of a VTE Occurred in a Very Young Adolescent. J Blood Lymph S1: 002. Doi: 10.4172/2165-7831.1000191

Copyright: © 2017 Micco PD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Article Usage
  • Total views: 1501
  • [From(publication date): 0-2017 - Dec 10, 2019]
  • Breakdown by view type
  • HTML page views: 1437
  • PDF downloads: 64
Top